drugset / Trial / NCT05183243

GH21 Capsules for Advanced Solid Tumors: A Study on Safety and Early Results

NCT05183243

Phase 1 Unknown 68 enrolled Suzhou Genhouse Bio Co., Ltd.
NaSingle-groupOpen-labelTreatment

Summary

Evaluate the safety and tolerability of GH21 in patients with advanced solid tumors. Estimate the maximum tolerated dose (MTD) in patients with advanced solid tumors.

Timeline

Start
2022-02-20
Primary completion
2024-12-31
Completion
2025-02-20

Drugs

EvaluationDrugModalityDoseRoute
Subject GH21 Unknown Oral